Form 8-K - Current report:
SEC Accession No. 0001104659-25-036837
Filing Date
2025-04-21
Accepted
2025-04-21 16:11:53
Documents
14
Period of Report
2025-04-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2512794d1_8k.htm   iXBRL 8-K 29083
2 EXHIBIT 10.1 tm2512794d1_10-1.htm EX-10.1 39323
  Complete submission text file 0001104659-25-036837.txt   252125

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rsls-20250415.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rsls-20250415_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rsls-20250415_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2512794d1_8k_htm.xml XML 3572
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37897 | Film No.: 25853266
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)